ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping ... on a trial of its COVID-19 vaccine pill.